Mirtazapine Accord Healthcare Ireland

Mirtazapine, the active ingredient in Mirtazapine Accord Healthcare Ireland, is a tetracyclic antidepressant presented as a tablet for oral use. It treats major depressive disorder in adult patients, helping to improve mood, sleep, and appetite.

GNH USA supplies Mirtazapine Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Mirtazapine is indicated for the treatment of major depressive disorder, a condition characterized by persistent low mood, loss of interest, and associated functional impairment. It is used in adult patients when other antidepressants are not tolerated or as a first‑line option.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Sedation: feeling unusually drowsy or sleepy. - Increased appetite: heightened desire for food, often leading to weight gain. - Dry mouth: reduced salivation causing discomfort. - Constipation: difficulty passing stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Weight gain: noticeable increase in body weight.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Severe allergic reactions: rash, swelling, or difficulty breathing. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Hepatic dysfunction: signs of liver injury such as jaundice. - Seizures: rare occurrence of convulsive episodes.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Hepatic function: assess liver enzymes and adjust use if impairment is present. - Suicidal ideation: monitor closely for emergence of suicidal thoughts, especially early in treatment. - Elderly patients: use cautiously due to increased sensitivity to sedation and falls. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms. - Renal impairment: consider dose adjustment in patients with reduced kidney function. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Linezolid or other reversible MAO inhibitors: may precipitate serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Alcohol: additive central nervous system depression leading to enhanced sedation. - Antihistamines: combined H1 blockade may intensify drowsiness.